Insmed Incorporated(INSM)Earnings, Financials & Key RatiosInsmed Incorporated (INSM) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
while revenue is scaling, the company's 2026Q1 net loss of $163.6 million and reliance on external capital to maintain a $582.2 million cash balance warrant a cautious, wait-and-see approach.
Insmed Incorporated (INSM) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Insmed Incorporated (INSM) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.76vs $0.96+21.1% | $306Mvs $301M+1.7% |
| Q1 2026 | Feb 19, 2026 | $1.54vs $1.07-43.9% | $264Mvs $231M+14.1% |
| Q4 2025 | Oct 30, 2025 | $1.75vs $1.33-31.6% | $142Mvs $115M+23.3% |
| Q3 2025 | Aug 7, 2025 | $1.70vs $1.30-30.8% | $107Mvs $104M+3.2% |
Recent stock market news and headlines for Insmed Incorporated (INSM)
Hannover, Germany, June 25, 2026 (GLOBE NEWSWIRE) -- EMBARC Announces Its Intention to Collaborate with Insmed on Landmark Interventional Study Evaluating Disease Modification Potential of Brensocatib in Bronchiectasis —Long-Term, Open-Label Study to Enroll Approximately 3,000 Patients Across Europe—
BRIDGEWATER, N.J., June 23, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the appointment of Samuele Butera as Senior Vice President, General Manager, Global Respiratory, effective today.
The Nasdaq 100 implemented its June quarterly rebalance, which shifts the tide for “the Qs.” Namely, the Invesco QQQ Trust (QQQ) and its cost-efficient sibling, the Invesco Nasdaq 100 ETF (QQQM).
Insmed is maintained at "Strong Buy" due to robust pipeline progress and expanding commercial execution. INSM's key catalysts include ARIKAYCE's sNDA submission for 1st-line MAC Lung Disease in H2 2026 and ongoing regulatory expansion efforts in Japan. TPIP advances with phase 3 PALM-PAH and PALM-ILD studies, targeting large PAH and PH-ILD markets with potential best-in-class, once-daily dosing.
Key metrics vs top competitors for Insmed Incorporated (INSM)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $112.84 | $24.46B | -17.60 | 66.73% | -210.54% | -249.28% | — | |
| $35.87 | $3.53B | -6.15 | 20.13% | -91.03% | — | — | |
| $321.59 | $42.91B | 138.02 | 65.19% | 13.46% | 98.29% | — | |
| $60.35 | $11.61B | 33.53 | 12.87% | 8.29% | 4.41% | — | |
| $19.79 | $2.09B | -2.78 | 15.58% | 2.98% | 4.89% | — | |
| $86.33 | $14.27B | -36.27 | 33.87% | -30.87% | -58.57% | — |
Insmed Incorporated (INSM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Insmed Incorporated (INSM) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 15, 2026·SEC
May 7, 2026·SEC
Apr 7, 2026·SEC
Get notified when INSM posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Insmed Incorporated (INSM) stock FAQ — growth, dividends, profitability & financials explained
Insmed Incorporated (INSM) reported $819.6M in revenue for fiscal year 2025. This represents a 81956300% increase from $0.0M in 1999.
Insmed Incorporated (INSM) grew revenue by 66.7% over the past year. This is strong growth.
Insmed Incorporated (INSM) reported a net loss of $1.18B for fiscal year 2025.
Insmed Incorporated (INSM) has a return on equity (ROE) of -249.3%. Negative ROE indicates the company is unprofitable.
Insmed Incorporated (INSM) had negative free cash flow of $951.6M in fiscal year 2025, likely due to heavy capital investments.
